Pfizer Reports Strong Q2 Sales Growth Fueled by New Vaccine Launches
Please note that we are not authorised to provide any investment advice. The content on this page is for information purposes only.
Pfizer Inc. reported strong second-quarter revenue on June 16, 2025, driven by successful launches of new vaccines and treatments. The U.S.-based pharmaceutical giant posted revenue of $23.8 billion, up 12% compared to the same period last year.
The company’s COVID-19 vaccine sales continued to decline but were offset by robust demand for its new RSV and influenza vaccines, which have gained rapid market adoption. Specialty medicines in oncology and rare diseases also contributed to revenue growth.
CEO Albert Bourla emphasized Pfizer’s commitment to innovation and expanding access to medicines worldwide. “Our pipeline remains robust, and we are focused on delivering breakthrough therapies that improve patient outcomes globally,” Bourla said.
Pfizer increased its R&D budget by 18% to accelerate development of mRNA vaccines and gene therapies. The company is also expanding manufacturing capacity to meet growing demand.
Despite pricing pressures and regulatory challenges, Pfizer maintained strong margins through operational efficiencies and portfolio optimization.
Pfizer shares rose 2.9% following the earnings report, as investors welcomed the company’s balanced growth approach.
